Taysha Gene Therapies Inc

Company Profile

Taysha Gene Therapies Inc had its IPO on 2020-09-24 under the ticker symbol TSHA.

The company operates in the Healthcare sector and Biotechnology industry. Taysha Gene Therapies Inc has a staff strength of 65 employees.

Stock update

Shares of Taysha Gene Therapies Inc opened at $3.45 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.95 - $3.45, and closed at $3.02.

This is a -13.71% slip from the previous day's closing price.

A total volume of 4,805,593 shares were traded at the close of the day’s session.

In the last one week, shares of Taysha Gene Therapies Inc have slipped by -16.8%.

Taysha Gene Therapies Inc's Key Ratios

Taysha Gene Therapies Inc has a market cap of $678.66 million, indicating a price to book ratio of 13.3011 and a price to sales ratio of 0.

In the last 12-months Taysha Gene Therapies Inc’s revenue was $9.60 million with a gross profit of $2.50 million and an EBITDA of $-77633000. The EBITDA ratio measures Taysha Gene Therapies Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Taysha Gene Therapies Inc’s operating margin was -822.1% while its return on assets stood at -44.08% with a return of equity of -745.28%.

In Q2, Taysha Gene Therapies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Taysha Gene Therapies Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Taysha Gene Therapies Inc’s profitability.

Taysha Gene Therapies Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.1345. Its price to sales ratio in the trailing 12-months stood at 0.

Taysha Gene Therapies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$81.54 million

Total Liabilities

$50.64 million

Operating Cash Flow

$48000.00

Capital Expenditure

$48000

Dividend Payout Ratio

0%

Taysha Gene Therapies Inc ended 2023 with $81.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $81.54 million while shareholder equity stood at $-37114000.00.

Taysha Gene Therapies Inc ended 2023 with $6.21 million in deferred long-term liabilities, $50.64 million in other current liabilities, 1000.00 in common stock, $-443661000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $45.08 million and cash and short-term investments were $45.08 million. The company’s total short-term debt was $1,638,000 while long-term debt stood at $38.35 million.

Taysha Gene Therapies Inc’s total current assets stands at $54.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $10.77 million and inventory worth $0.

In 2023, Taysha Gene Therapies Inc's operating cash flow was $48000.00 while its capital expenditure stood at $48000.

Comparatively, Taysha Gene Therapies Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$3.02

52-Week High

$3.89

52-Week Low

$0.5

Analyst Target Price

$5.72

Taysha Gene Therapies Inc stock is currently trading at $3.02 per share. It touched a 52-week high of $3.89 and a 52-week low of $3.89. Analysts tracking the stock have a 12-month average target price of $5.72.

Its 50-day moving average was $1.55 and 200-day moving average was $1.29 The short ratio stood at 0.08 indicating a short percent outstanding of 0%.

Around 3933.1% of the company’s stock are held by insiders while 2868.5% are held by institutions.